메뉴 건너뛰기




Volumn 289, Issue 2, 2010, Pages 228-236

Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274

Author keywords

Drug resistance; MET; Point mutations; Receptor tyrosine kinases; SU11274

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR; STAT3 PROTEIN;

EID: 76849098324     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.08.017     Document Type: Article
Times cited : (19)

References (33)
  • 1
    • 0036678472 scopus 로고    scopus 로고
    • Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop
    • Roumiantsev S., Shah N.P., Gorre M.E., Nicoll J., Brasher B.B., Sawyers C.L., and Van Etten R.A. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc. Natl. Acad. Sci. USA 99 (2002) 10700-10705
    • (2002) Proc. Natl. Acad. Sci. USA , vol.99 , pp. 10700-10705
    • Roumiantsev, S.1    Shah, N.P.2    Gorre, M.E.3    Nicoll, J.4    Brasher, B.B.5    Sawyers, C.L.6    Van Etten, R.A.7
  • 3
    • 20444459499 scopus 로고    scopus 로고
    • The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy
    • Dowell J.E., and Minna J.D. The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy. Nat. Clin. Pract. Oncol. 1 (2004) 2-3
    • (2004) Nat. Clin. Pract. Oncol. , vol.1 , pp. 2-3
    • Dowell, J.E.1    Minna, J.D.2
  • 4
    • 18244371651 scopus 로고    scopus 로고
    • Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
    • Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., Kris M.G., and Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2 (2005) e73
    • (2005) PLoS Med , vol.2
    • Pao, W.1    Miller, V.A.2    Politi, K.A.3    Riely, G.J.4    Somwar, R.5    Zakowski, M.F.6    Kris, M.G.7    Varmus, H.8
  • 5
    • 0035573938 scopus 로고    scopus 로고
    • Hepatocyte growth factor expression in human cancer and therapy with specific inhibitors
    • Haddad R., Lipson K.E., and Webb C.P. Hepatocyte growth factor expression in human cancer and therapy with specific inhibitors. Anticancer Res. 21 (2001) 4243-4252
    • (2001) Anticancer Res. , vol.21 , pp. 4243-4252
    • Haddad, R.1    Lipson, K.E.2    Webb, C.P.3
  • 7
    • 0036221263 scopus 로고    scopus 로고
    • Dysregulation of Met receptor tyrosine kinase activity in invasive tumors
    • Danilkovitch-Miagkova A., and Zbar B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J. Clin. Invest. 109 (2002) 863-867
    • (2002) J. Clin. Invest. , vol.109 , pp. 863-867
    • Danilkovitch-Miagkova, A.1    Zbar, B.2
  • 8
    • 1342321789 scopus 로고    scopus 로고
    • Targeting c-Kit mutations: basic science to novel therapies
    • Sattler M., and Salgia R. Targeting c-Kit mutations: basic science to novel therapies. Leukemia Res. 28 Suppl. 1 (2004) S11-20
    • (2004) Leukemia Res. , vol.28 , Issue.SUPPL. 1
    • Sattler, M.1    Salgia, R.2
  • 13
    • 0141988690 scopus 로고    scopus 로고
    • c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions
    • Ma P.C., Kijima T., Maulik G., Fox E.A., Sattler M., Griffin J.D., Johnson B.E., and Salgia R. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res. 63 (2003) 6272-6281
    • (2003) Cancer Res. , vol.63 , pp. 6272-6281
    • Ma, P.C.1    Kijima, T.2    Maulik, G.3    Fox, E.A.4    Sattler, M.5    Griffin, J.D.6    Johnson, B.E.7    Salgia, R.8
  • 14
    • 0346753584 scopus 로고    scopus 로고
    • Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx
    • Aebersold D.M., Landt O., Berthou S., Gruber G., Beer K.T., Greiner R.H., and Zimmer Y. Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx. Oncogene 22 (2003) 8519-8523
    • (2003) Oncogene , vol.22 , pp. 8519-8523
    • Aebersold, D.M.1    Landt, O.2    Berthou, S.3    Gruber, G.4    Beer, K.T.5    Greiner, R.H.6    Zimmer, Y.7
  • 21
    • 0242268455 scopus 로고    scopus 로고
    • Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a
    • Schiering N., Knapp S., Marconi M., Flocco M.M., Cui J., Perego R., Rusconi L., and Cristiani C. Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a. Proc. Natl. Acad. Sci. USA 100 (2003) 12654-12659
    • (2003) Proc. Natl. Acad. Sci. USA , vol.100 , pp. 12654-12659
    • Schiering, N.1    Knapp, S.2    Marconi, M.3    Flocco, M.M.4    Cui, J.5    Perego, R.6    Rusconi, L.7    Cristiani, C.8
  • 22
    • 0030945871 scopus 로고    scopus 로고
    • Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors
    • Mohammadi M., McMahon G., Sun L., Tang C., Hirth P., Yeh B.K., Hubbard S.R., and Schlessinger J. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 276 (1997) 955-960
    • (1997) Science , vol.276 , pp. 955-960
    • Mohammadi, M.1    McMahon, G.2    Sun, L.3    Tang, C.4    Hirth, P.5    Yeh, B.K.6    Hubbard, S.R.7    Schlessinger, J.8
  • 23
    • 0035400394 scopus 로고    scopus 로고
    • Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto-oncogene: modeling studies
    • Miller M., Ginalski K., Lesyng B., Nakaigawa N., Schmidt L., and Zbar B. Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto-oncogene: modeling studies. Proteins 44 (2001) 32-43
    • (2001) Proteins , vol.44 , pp. 32-43
    • Miller, M.1    Ginalski, K.2    Lesyng, B.3    Nakaigawa, N.4    Schmidt, L.5    Zbar, B.6
  • 26
    • 0037075606 scopus 로고    scopus 로고
    • The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met
    • Petrelli A., Gilestro G.F., Lanzardo S., Comoglio P.M., Migone N., and Giordano S. The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met. Nature 416 (2002) 187-190
    • (2002) Nature , vol.416 , pp. 187-190
    • Petrelli, A.1    Gilestro, G.F.2    Lanzardo, S.3    Comoglio, P.M.4    Migone, N.5    Giordano, S.6
  • 27
    • 3142761786 scopus 로고    scopus 로고
    • A conserved DpYR motif in the juxtamembrane domain of the Met receptor family forms an atypical c-Cbl/Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation
    • Peschard P., Ishiyama N., Lin T., Lipkowitz S., and Park M. A conserved DpYR motif in the juxtamembrane domain of the Met receptor family forms an atypical c-Cbl/Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation. J. Biol. Chem. 279 (2004) 29565-29571
    • (2004) J. Biol. Chem. , vol.279 , pp. 29565-29571
    • Peschard, P.1    Ishiyama, N.2    Lin, T.3    Lipkowitz, S.4    Park, M.5
  • 28
    • 0034693753 scopus 로고    scopus 로고
    • Met receptor tyrosine kinase: enhanced signaling through adapter proteins
    • Furge K.A., Zhang Y.W., and Vande Woude G.F. Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene 19 (2000) 5582-5589
    • (2000) Oncogene , vol.19 , pp. 5582-5589
    • Furge, K.A.1    Zhang, Y.W.2    Vande Woude, G.F.3
  • 30
    • 0036896226 scopus 로고    scopus 로고
    • Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion
    • Lorenzato A., Olivero M., Patane S., Rosso E., Oliaro A., Comoglio P.M., and Di Renzo M.F. Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. Cancer Res. 62 (2002) 7025-7030
    • (2002) Cancer Res. , vol.62 , pp. 7025-7030
    • Lorenzato, A.1    Olivero, M.2    Patane, S.3    Rosso, E.4    Oliaro, A.5    Comoglio, P.M.6    Di Renzo, M.F.7
  • 31
    • 0038375012 scopus 로고    scopus 로고
    • Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib
    • Corbin A.S., La Rosee P., Stoffregen E.P., Druker B.J., and Deininger M.W. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 101 (2003) 4611-4614
    • (2003) Blood , vol.101 , pp. 4611-4614
    • Corbin, A.S.1    La Rosee, P.2    Stoffregen, E.P.3    Druker, B.J.4    Deininger, M.W.5
  • 32
    • 44449151030 scopus 로고    scopus 로고
    • Drug development of MET inhibitors: targeting oncogene addiction and expedience
    • Comoglio P.M., Giordano S., and Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat. Rev. Drug. Discov. 7 (2008) 504-516
    • (2008) Nat. Rev. Drug. Discov. , vol.7 , pp. 504-516
    • Comoglio, P.M.1    Giordano, S.2    Trusolino, L.3
  • 33
    • 67649393456 scopus 로고    scopus 로고
    • MET pathway as a therapeutic target
    • Kim E.S., and Salgia R. MET pathway as a therapeutic target. J. Thorac. Oncol. 4 (2009) 444-447
    • (2009) J. Thorac. Oncol. , vol.4 , pp. 444-447
    • Kim, E.S.1    Salgia, R.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.